IDiyas

For the Inventor, By the Inventor

Lörrach, Germany

Nikolaus Johannes Stiefl

USPTO Granted Patents = 16 

 

Average Co-Inventor Count = 6.3

ph-index = 5

Forward Citations = 59(Granted Patents)


Location History:

  • Lorrach, DE (2012 - 2013)
  • Basel, CH (2012 - 2013)
  • Lörrach, DE (2011 - 2022)

Company Filing History:

goldMedal16 out of 3,923 
 
Novartis Ag
 patents

Years Active: 2011-2025

Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 12466808 - Aminopyridine derivatives and their use as selective ALK-2 inhibitors (2025-11-11),
2. 12168012 - NLRP3 inflammasome inhibitors (2024-12-17),
3. 12139471 - NLRP3 inflammasome inhibitors (2024-11-12),
4. 11254653 - NLRP3 inflammasome inhibitors (2022-02-22),
5. 11208399 - NLRP3 inflammasome inhibitors (2021-12-28),
6. 11160797 - Pyridinone derivatives and their use as selective ALK-2 inhibitors (2021-11-02),
7. 10947218 - Aminopyridine derivatives and their use as selective ALK-2 inhibitors (2021-03-16),
8. 10710980 - Aminopyridine derivatives and their use as selective ALK-2 inhibitors (2020-07-14),
9. 9079897 - Imidazo-pyridine derivatives as activin-like receptor kinase (ALK4 or ALK5) inhibitors (2015-07-14),
10. 8791100 - Aryl benzylamine compounds (2014-07-29),
11. 8431578 - Organic compounds (2013-04-30),
12. 8367662 - Organic compounds (2013-02-05),
13. 8343966 - Organic compounds (2013-01-01),
14. 8314112 - Pyrrolopyrimidines and pyrrolopyridines (2012-11-20),
15. 8143253 - Organic compounds (2012-03-27),

Title: Innovator Spotlight - Nikolaus Johannes Stiefl

Introduction:

Nikolaus Johannes Stiefl, a talented inventor based in Lörrach, Germany, has made significant contributions to the field of medical research through his innovative patents. With a total of 13 patents to his name, Stiefl is a pioneering figure in the development of NLRP3 inflammasome inhibitors.

Latest Patents:

Stiefl's latest patents revolve around the creation of novel pyridazin-3-yl phenol compounds that effectively inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. These inventions not only include the compounds' chemical structures but also detail their preparation processes, pharmaceutical compositions, and applications in treating diseases and disorders associated with NLRP3.

Career Highlights:

Currently affiliated with Novartis AG, a renowned pharmaceutical company, Stiefl continues to push the boundaries of medical science with his groundbreaking research. His expertise in developing innovative solutions for complex medical conditions has earned him recognition within the industry.

Collaborations:

Stiefl's collaborative efforts have been instrumental in advancing his research. Working alongside accomplished colleagues such as Dimitrios Lizos and Sven Weiler, he has exchanged ideas, shared insights, and collectively contributed to the success of various projects.

Conclusion:

In conclusion, Nikolaus Johannes Stiefl stands out as a prolific inventor whose passion for medical innovation has led to the creation of groundbreaking NLRP3 inflammasome inhibitors. His dedication to improving healthcare and exploring novel solutions underscores his commitment to shaping the future of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…